In three to seven percent of NSCLC tumors, anaplastic lymphoma kinase (ALK) gene rearrangements occur and lead to the expression of a transforming fusion kinase [4] targeted by crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.